News item

Xenikos secures investment of 30 million dollars

Xenikos B.V. is a clinical-stage biopharmaceutical company, developing innovative new immunotherapies, based on conjugated antibodies, designed to improve patient health and quality of life. Currently they are developing a novel therapy for treating acute graft-versus-host disease (aGVHD).


“We are extremely pleased to have the support of these top-tier investors not just in terms of financing but also for the expertise and insight they bring to Xenikos. We very much look forward to welcoming Dr. Edwards and Dr. Simson to our Board of Directors at this important stage of development for the Company,” said Dr. Ypke van Oosterhout, Chief Executive Officer of Xenikos. “This round of financing is a critical milestone in our Company’s history, helping us bring T-Guard to market for treating steroid-resistant aGVHD in both the US and the EU. Based on the encouraging results of Phase 1/2 testing, we are confident that T Guard has the potential to help cure patients who develop this devastating and often fatal condition. We are fully committed to moving T-Guard into Phase 3 testing as soon as possible.”

Share this news

Share on facebook
Share on twitter
Share on linkedin

Fighting malaria is fighting poverty

Diseases that spread across the globe come and go, but malaria has been around for thousands of years. The number of people affected by the disease is on the rise and it hits lower-income countries the hardest. So how can we fight malaria, and what will it bring to the world if we manage to do so? Koen Dechering, CEO of TropIQ Health Sciences, explains why more needs to be done and how his company contributes to eradicating the disease once and for all.

Read More »

Subscribe the NTC Newsletter

We care about your privacy: Read more

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!